BioVU Archive — Page 4 of 8
-
May 5, 2022
Gene network linked to Type 2 diabetes
Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease. -
April 26, 2022
Calculating risk for uterine fibroids
Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies. -
April 6, 2022
Major grant renewal to provide five more years of support for VICTR
Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health. -
March 7, 2022
Study finds World Trade Center responders at higher risk for blood cancer-associated mutations
A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease -
January 10, 2022
Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU. -
December 2, 2021
Gene discoveries give new hope to people who stutter
New research shows the potential to identify therapeutic directions that could improve outcomes for people who stutter. -
December 2, 2021
Study links depression scores, white blood cell count